ACTH (7-38), human

Product Name: ACTH (7-38), human

Sequence One Letter Code: FRWGKPVGKKRRPVKVYPNGAEDESAEAFPLE

Sequence Three Letter Code: H-Phe-Arg-Trp-Gly-Lys-Pro-Val-Gly-Lys-Lys-Arg-Arg-Pro-Val-Lys-Val-Tyr-Pro-Asn-Gly-Ala-Glu-Asp-Glu-Ser-Ala-Glu-Ala-Phe-Pro-Leu-Glu-OH

Cas No: 68563-24-6

Chemical Formula:C167H257N47O46

Molecular Weight: 3659.4

Purity: 95%

Form: Lyophilized

Storage Conditions: - 20 °C

Research Area: Endocrinology Disease Research

SMILES: C[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)O)NC(=O)CNC(=O)[C@H](CC(=O)N)NC(=O)[C@@H]3CCCN3C(=O)[C@H](CC4=CC=C(C=C4)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]5CCCN5C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](C(C)C)NC(=O)[C@@H]6CCCN6C(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](CC7=CNC8=CC=CC=C87)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC9=CC=CC=C9)N

IUPAC: (2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-4-amino-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-6-amino-2-[[2-[[(2S)-2-[[(2S)-1-[(2S)-6-amino-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]acetyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]acetyl]amino]hexanoyl]amino]hexanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]hexanoyl]amino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]pyrrolidine-2-carbonyl]amino]-4-oxobutanoyl]amino]acetyl]amino]propanoyl]amino]-4-carboxybutanoyl]amino]-3-carboxypropanoyl]amino]-4-carboxybutanoyl]amino]-3-hydroxypropanoyl]amino]propanoyl]amino]-4-carboxybutanoyl]amino]propanoyl]amino]-3-phenylpropanoyl]pyrrolidine-2-carbonyl]amino]-4-methylpentanoyl]amino]pentanedioic acid

INCHIKEY: ZKALIGRYJXFMNS-XBDDSDALSA-N

INCHI:

InChI=1S/C167H257N47O46/c1-87(2)75-113(150(245)200-112(164(259)260)59-63-131(227)228)203-153(248)120-48-31-73-213(120)162(257)117(77-95-37-16-13-17-38-95)205-138(233)93(11)188-142(237)107(56-60-128(221)222)192-137(232)92(10)189-152(247)119(86-215)207-148(243)109(58-62-130(225)226)197-151(246)116(81-132(229)230)202-147(242)108(57-61-129(223)224)193-136(231)91(9)187-125(218)83-184-141(236)115(80-124(173)217)204-154(249)121-49-32-74-214(121)163(258)118(78-96-52-54-98(216)55-53-96)206-159(254)134(89(5)6)208-149(244)104(43-22-26-66-170)198-158(253)135(90(7)8)210-156(251)123-51-34-72-212(123)161(256)111(47-30-70-182-167(178)179)199-145(240)106(46-29-69-181-166(176)177)196-144(239)103(42-21-25-65-169)195-143(238)102(41-20-24-64-168)190-126(219)85-186-157(252)133(88(3)4)209-155(250)122-50-33-71-211(122)160(255)110(44-23-27-67-171)191-127(220)84-185-140(235)114(79-97-82-183-101-40-19-18-39-99(97)101)201-146(241)105(45-28-68-180-165(174)175)194-139(234)100(172)76-94-35-14-12-15-36-94/h12-19,35-40,52-55,82,87-93,100,102-123,133-135,183,215-216H,20-34,41-51,56-81,83-86,168-172H2,1-11H3,(H2,173,217)(H,184,236)(H,185,235)(H,186,252)(H,187,218)(H,188,237)(H,189,247)(H,190,219)(H,191,220)(H,192,232)(H,193,231)(H,194,234)(H,195,238)(H,196,239)(H,197,246)(H,198,253)(H,199,240)(H,200,245)(H,201,241)(H,202,242)(H,203,248)(H,204,249)(H,205,233)(H,206,254)(H,207,243)(H,208,244)(H,209,250)(H,210,251)(H,221,222)(H,223,224)(H,225,226)(H,227,228)(H,229,230)(H,259,260)(H4,174,175,180)(H4,176,177,181)(H4,178,179,182)/t91-,92-,93-,100-,102-,103-,104-,105-,106-,107-,108-,109-,110-,111-,112-,113-,114-,115-,116-,117-,118-,119-,120-,121-,122-,123-,133-,134-,135-/m0/s1

Source / Species: human

Conjugation: Unconjugated

Code Nacres: NA.26

Application: ACTH (7–38), human is a synthetic peptide fragment corresponding to residues 7–38 of adrenocorticotropic hormone (ACTH 1–39), also referred to as corticotropin-inhibiting peptide (CIP). This biologically active fragment functions as an ACTH receptor antagonist, blocking ACTH-mediated signaling without stimulating corticosteroid production. It is widely used in endocrine research to investigate receptor–ligand interactions, adrenal signaling pathways, and regulation of the hypothalamic–pituitary–adrenal (HPA) axis. ACTH (7–38) supports mechanistic studies of ACTH receptor modulation, stress-response signaling, and pharmacological inhibition of ACTH-dependent pathways. The peptide is suitable for in vitro receptor assays, functional antagonism studies, and endocrine pathway characterization related to adrenal physiology and hormonal regulation.

Current Research: ACTH (7–38), also known as corticotropin-inhibiting peptide (CIP), represents a truncated fragment of full-length ACTH (1–39) that retains receptor-binding capacity while lacking intrinsic steroidogenic activity. This unique pharmacological profile has made ACTH (7–38) an important tool for dissecting melanocortin 2 receptor (MC2R) signaling and the regulation of adrenal glucocorticoid production. By competitively antagonizing ACTH binding to MC2R, the peptide enables selective suppression of ACTH-dependent cAMP generation and downstream steroid biosynthesis without directly activating cortisol secretion. Current research increasingly focuses on precise modulation of the hypothalamic–pituitary–adrenal (HPA) axis, particularly in stress-related disorders, Cushing’s disease, adrenal hyperplasia, and inflammatory conditions influenced by glucocorticoid signaling. ACTH (7–38) is widely used in in vitro adrenal cell models and receptor-transfected systems to characterize ligand–receptor interactions, evaluate MC2R coupling to Gs proteins, and quantify cAMP-dependent signaling responses. Competitive binding assays incorporating ACTH (7–38) provide insight into receptor affinity, antagonist potency, and structure–activity relationships within melanocortin peptides. Beyond classical adrenal steroidogenesis, emerging evidence suggests that ACTH and melanocortin receptors participate in immune modulation, metabolic regulation, and central nervous system signaling. ACTH (7–38) supports mechanistic studies aimed at distinguishing ACTH-driven endocrine effects from extra-adrenal melanocortin receptor activity. This distinction is particularly relevant in inflammatory and autoimmune research, where melanocortin pathways influence cytokine production and immune cell behavior. Pharmacological investigations also utilize ACTH (7–38) to model partial blockade of stress hormone signaling. In experimental systems examining stress-induced metabolic dysregulation, chronic inflammation, or neuroendocrine adaptation, the peptide provides a controlled means of attenuating ACTH-mediated cortisol release. This approach enables researchers to probe feedback mechanisms within the HPA axis, including glucocorticoid receptor–mediated suppression of hypothalamic corticotropin-releasing hormone (CRH) and pituitary ACTH synthesis. In translational endocrinology, defined ACTH fragments are valuable for validating receptor assays and screening compounds targeting MC2R or related melanocortin receptors. ACTH (7–38) serves as a reference antagonist in assay development platforms measuring receptor activation, second messenger production, or steroid output. These standardized systems are increasingly important for therapeutic discovery efforts focused on modulating adrenal function without inducing systemic hypercortisolism. Collectively, current research highlights ACTH (7–38) as a functionally selective antagonist that enables detailed investigation of ACTH receptor pharmacology and HPA axis regulation. Its ability to block ACTH-mediated signaling without triggering corticosteroid production makes it a versatile tool for endocrine research, stress biology studies, and development of targeted interventions in adrenal and neuroendocrine disorders.